Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Name: Kaimen Rigor review — Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.
Item: Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.
Rating: 100
Author: Alpha1

Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, André F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 0 high issues for “Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03415-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8d38bda8-a710-48b3-aa54-a0023afd616d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8d38bda8-a710-48b3-aa54-a0023afd616d/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 0 high issues for “Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

8eb3770430b28ebc8fddfcc1efb6f720c7e3c1bcf52d76407c3803d8824a7ef3

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Paper source

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on pathological complete response (pCR), a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking pCR to clinical outcomes in this specific ER+/HER2- population, beyond a general meta-analysis reference. The other primary endpoint, event-free survival, is not yet mature.
“Dual primary endpoints were pathological complete response and event-free survival in the intention-to-treat population. ... Event-free survival was not mature in this analysis.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial. The methodology is strong across all dimensions, with clear randomization, blinding, power analysis, and statistical methods. Minor reporting gaps include lack of explicit CONSORT mention and regulatory compliance statement, but these do not undermine the overall integrity.

Both reviewers classified the study as interventional, and no divergence was noted. The evaluation covered all eight dimensions; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests, so the statistical analysis is not fully independently verified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior studies (I-SPY2, KEYNOTE-522) and a meta-analysis correlating pCR with EFS/OS, providing a strong rationale for the trial. It also acknowledges the heterogeneity of ER+ disease and the need for better treatments in high-risk subgroups. Limitations of prior research are addressed by designing a phase 3 trial with dual primary endpoints.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific premise with prior work, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

“For these patients, reported pathological complete response (pCR) rates range from 0% to 18% and event-free survival (EFS) rates are similar to those of patients with triple-negative breast cancer (TNBC).”

paraphrase[Introduction, paragraph 2]

“Building on these results, KEYNOTE-756 was designed as a randomized, double-blind, phase 3 study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo plus endocrine therapy.”

paraphrase[Introduction, paragraph 2]

“The study builds on phase 2 I-SPY2 results and phase 3 KEYNOTE-522 results, addressing the need for a definitive phase 3 trial in ER+/HER2- disease.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

“Combination therapy with immune checkpoint inhibitors plus chemotherapy induces changes to the tumor microenvironment that may enhance endogenous anticancer immunity, reduce tumor volume and increase response rate compared with chemotherapy alone.”

paraphrase[Introduction, paragraph 2]

Randomization method (central interactive voice-response system) and unit (patient) are described. Blinding is double-blind with placebo control. Power analysis is provided (>99% power for pCR, 84% for EFS). Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT and as-treated populations. Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

“Patients were randomly assigned (in a 1:1 ratio) to the pembrolizumab–chemotherapy arm or the placebo–chemotherapy arm using a central interactive voice-response system with an integrated web-response system.”

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“In this randomized, double-blind trial (ClinicalTrials.gov identifier, NCT03725059)”

“With an enrollment of approximately 1,240 patients, the trial had >99% power to detect a true difference of 15 percentage points for the comparison of the rate of pCR (stage ypT0/Tis ypN0) between the treatment arms at a one-sided α level of 0.005.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“In this randomized, double-blind trial (ClinicalTrials.gov identifier, NCT03725059), patients received treatment in neoadjuvant and adjuvant phases.”

Statistical analysisFind in source

Sex is reported (six men included), age is reported (median and range), and demographics are detailed in Table 1. Sex justification is not applicable as both sexes are enrolled. Species/strain/housing are not applicable for human trial. Demographics include age, sex, region, PD-L1 status, ECOG, tumor stage, grade, ER positivity, and menopausal status.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported, including sex, age, and demographics; species/strain/housing are not applicable for a human trial.

Evidence

“A total of six men with ER + and HER2 − breast cancer were included in the study (three in each treatment arm).”

Table 1Find in source

“Median (range) | 49 (24–82) | 49 (19–78)”

Table 1Find in source

“Demographics and baseline disease characteristics were balanced between treatment arms (Table ).”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographics and baseline characteristics are well reported, including age, sex, and menopausal status.

Evidence

“A total of six men with ER + and HER2 − breast cancer were included in the study (three in each treatment arm).”

Table 1Find in source

paraphrase[Table 1]

“Age (year) Median (range) 49 (24–82) 49 (19–78)”

paraphrase[Table 1]

“Country/region—no. (%) China 88 (13.9) 91 (14.2)”

The protocol was approved by an ethics body at each study site, and patients provided written informed consent. Regulatory compliance is implied by adherence to ICH-GCP and the Declaration of Helsinki, though not explicitly named. The ethics statement is adequate as it names the approving body (ethics body at each site).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“The protocol was approved by an ethics body at each study site (see for a list of study sites).”

MethodsFind in source

“Patients provided written informed consent”

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines, as is standard for phase 3 trials.”

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately reported.

Evidence

“The protocol was approved by an ethics body at each study site (see for a list of study sites).”

MethodsFind in source

“Patients provided written informed consent”

MethodsFind in source

The investigational product (pembrolizumab) is identified with dose and regimen. The PD-L1 IHC 22C3 pharmDx assay is identified with vendor. Statistical software (SAS v9.4) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources are adequately identified, including the investigational product and software.

Evidence

“patients received four cycles of intravenous pembrolizumab (200 mg) or placebo once Q3W plus paclitaxel QW (80 mg m − 2 ; first neoadjuvant treatment)”

MethodsFind in source

“PD-L1 expression in new or recent core needle biopsy samples was assessed at a central laboratory using PD-L1 IHC 22C3 pharmDx (Agilent Technologies).”

MethodsFind in source

“Statistical analyses were conducted using SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (pembrolizumab) and key reagents are adequately identified.

Evidence

“patients received four cycles of intravenous pembrolizumab (200 mg) or placebo once Q3W plus paclitaxel QW (80 mg m − 2 ; first neoadjuvant treatment)”

MethodsFind in source

“PD-L1 expression in new or recent core needle biopsy samples was assessed at a central laboratory using PD-L1 IHC 22C3 pharmDx (Agilent Technologies).”

MethodsFind in source

“Statistical analyses were conducted using SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

The primary analysis uses the stratified Miettinen–Nurminen method, which is named. Exact p-values are reported (P = 0.00005). Effect sizes with 95% CIs are reported. Software is identified. Data presentation includes per-group n and CIs. Assumptions are handled by design (stratified analysis). Mathematical plausibility checks are not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation.

Evidence

“We used the stratified Miettinen–Nurminen method , with weights proportional to the stratum sample size, to compare between-arm differences in percentages of patients with a pCR.”

Statistical analysisFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals.

Evidence

“We used the stratified Miettinen–Nurminen method , with weights proportional to the stratum sample size, to compare between-arm differences in percentages of patients with a pCR.”

Statistical analysisFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

The data availability statement provides a concrete route for data access via the MSD data-sharing website and a review committee. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete managed-access mechanism.

Evidence

paraphrase[Data availability section]

“The MSD data-sharing website (available at engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request.”

“Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access mechanism.

Evidence

paraphrase[Data availability section]

“The MSD data-sharing website (available at engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request.”

The trial is registered (NCT03725059). Methods are detailed. Limitations are discussed (e.g., EFS not mature, subgroup analyses underpowered). Conclusions are proportional, noting the need for replication. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“ClinicalTrials.gov identifier: NCT03725059”

AbstractFind in source

“However, these results should be interpreted with caution as these subgroups are underpowered, and the only objective of subgroup analyses is to explore convergent validity.”

Discussion ¶2Find in source

“To establish confidence, replication in other trials is absolutely essential.”

Discussion ¶2Find in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, funding, and COI statements, and limitations are discussed.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov identifier: NCT03725059 (https://clinicaltrials.gov/study/NCT03725059).”

“However, these results should be interpreted with caution as these subgroups are underpowered, and the only objective of subgroup analyses is to explore convergent validity.”

Discussion ¶2Find in source

“Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 27 references by DOI: 23 verified — 4 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (e.g., explicit CONSORT and regulatory compliance statements) and the limited independent statistical verification, but these do not warrant a correction. The trial's conclusions are appropriately cautious and supported by the data.

1.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly state compliance with the CONSORT reporting guideline.
Both reviewers flagged the absence of an explicit CONSORT mention, which is a standard expectation for RCT reporting.
2.
MEDIUMethics
In the Methods, explicitly state that the trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines.
One reviewer noted that regulatory compliance is only implied, and an explicit statement strengthens the ethics reporting.
3.
MEDIUMreporting
In the Methods, provide more detail on the randomization sequence generation (e.g., block size) to enhance reproducibility.
The randomization method is described, but additional details on sequence generation would improve transparency.
4.
MEDIUMstatistics
In the Statistical analysis section, clarify the handling of missing data for EFS and other secondary endpoints.
The paper does not explicitly describe missing data imputation or handling, which is important for survival analyses.
5.
MEDIUMdata code
In the Data Availability section, clarify the timeframe for data availability after product approval.
One reviewer suggested specifying when data will be available, which is a common requirement for data-sharing statements.
6.
MEDIUMreporting
In the Methods, specify the exact version of the AJCC staging criteria used for pCR assessment.
Providing the staging version ensures consistency and reproducibility of the pCR definition.
7.
MEDIUMstatistics
In the Results, report the number of patients with missing pCR data to fully address missing-data handling.
Transparency about missing data is essential for interpreting the primary endpoint.
8.
MEDIUMreporting
In the Discussion, explicitly acknowledge the lack of independent replication of the pCR finding within this trial.
While the paper notes the need for replication, explicitly stating that this is a single trial without independent replication would be clearer.
9.
MEDIUMreporting
In the Methods, describe the process for central confirmation of ER+/HER2- status to ensure consistency across sites.
Central confirmation of biomarker status is critical for trial validity and should be described.
10.
MEDIUMstatistics
In the Results, consider presenting p-values for secondary endpoints to fully report all outcomes.
Reporting p-values for secondary endpoints would enhance completeness, though it is not mandatory.
11.
LOWcopyedit
Fix the author list formatting: 'O’Shaughnessy Joyce Liu Zhenzhen' should have proper punctuation and spacing.
Correct author formatting is essential for indexing and professional presentation.
12.
LOWcopyedit
In the Abstract, consider reporting the p-value as '<0.001' for readability, or keep exact value consistently.
Consistency in p-value reporting improves readability.
13.
LOWcopyedit
In the Methods, clarify that the stratification by PD-L1 status applies only to Eastern Europe.
The sentence could be rephrased for better flow and clarity.
14.
LOWcopyedit
Ensure consistent spacing around plus/minus signs in 'ER + /HER2 − breast cancer' throughout the manuscript.
Minor formatting consistency improves professional appearance.
15.
LOWcopyedit
In the Results, Safety section, remove the space after the hyphen: 'non-Q wave' should be 'non-Q wave'.
Typographical spacing issue that should be corrected.
16.
LOWcopyedit
In the Methods, Statistical analysis, resolve the reference placeholder: 'The graphical method discussed in ref. was applied' should cite the specific reference.
Unresolved reference placeholders are a copyedit issue that must be fixed before publication.

Full text (52,247 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03415-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8d38bda8-a710-48b3-aa54-a0023afd616d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8d38bda8-a710-48b3-aa54-a0023afd616d/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 0 high issues for “Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

8eb3770430b28ebc8fddfcc1efb6f720c7e3c1bcf52d76407c3803d8824a7ef3

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on pathological complete response (pCR), a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking pCR to clinical outcomes in this specific ER+/HER2- population, beyond a general meta-analysis reference. The other primary endpoint, event-free survival, is not yet mature.
“Dual primary endpoints were pathological complete response and event-free survival in the intention-to-treat population. ... Event-free survival was not mature in this analysis.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

1 finding · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific premise with prior work, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

“The study builds on phase 2 I-SPY2 results and phase 3 KEYNOTE-522 results, addressing the need for a definitive phase 3 trial in ER+/HER2- disease.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“In this randomized, double-blind trial (ClinicalTrials.gov identifier, NCT03725059)”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“In this randomized, double-blind trial (ClinicalTrials.gov identifier, NCT03725059), patients received treatment in neoadjuvant and adjuvant phases.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported, including sex, age, and demographics; species/strain/housing are not applicable for a human trial.

Evidence

“A total of six men with ER + and HER2 − breast cancer were included in the study (three in each treatment arm).”

Table 1Find in source

“Median (range) | 49 (24–82) | 49 (19–78)”

Table 1Find in source

“Demographics and baseline disease characteristics were balanced between treatment arms (Table ).”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographics and baseline characteristics are well reported, including age, sex, and menopausal status.

Evidence

“A total of six men with ER + and HER2 − breast cancer were included in the study (three in each treatment arm).”

Table 1Find in source

paraphrase[Table 1]

“Age (year) Median (range) 49 (24–82) 49 (19–78)”

paraphrase[Table 1]

“Country/region—no. (%) China 88 (13.9) 91 (14.2)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“The protocol was approved by an ethics body at each study site (see for a list of study sites).”

MethodsFind in source

“Patients provided written informed consent”

MethodsFind in source

paraphrase[Methods, Trial design and treatment]

“The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines, as is standard for phase 3 trials.”

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately reported.

Evidence

“The protocol was approved by an ethics body at each study site (see for a list of study sites).”

MethodsFind in source

“Patients provided written informed consent”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources are adequately identified, including the investigational product and software.

Evidence

“patients received four cycles of intravenous pembrolizumab (200 mg) or placebo once Q3W plus paclitaxel QW (80 mg m − 2 ; first neoadjuvant treatment)”

MethodsFind in source

“PD-L1 expression in new or recent core needle biopsy samples was assessed at a central laboratory using PD-L1 IHC 22C3 pharmDx (Agilent Technologies).”

MethodsFind in source

“Statistical analyses were conducted using SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (pembrolizumab) and key reagents are adequately identified.

Evidence

“patients received four cycles of intravenous pembrolizumab (200 mg) or placebo once Q3W plus paclitaxel QW (80 mg m − 2 ; first neoadjuvant treatment)”

MethodsFind in source

“PD-L1 expression in new or recent core needle biopsy samples was assessed at a central laboratory using PD-L1 IHC 22C3 pharmDx (Agilent Technologies).”

MethodsFind in source

“Statistical analyses were conducted using SAS v9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, effect sizes with CIs, and appropriate data presentation.

Evidence

“We used the stratified Miettinen–Nurminen method , with weights proportional to the stratum sample size, to compare between-arm differences in percentages of patients with a pCR.”

Statistical analysisFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals.

Evidence

“We used the stratified Miettinen–Nurminen method , with weights proportional to the stratum sample size, to compare between-arm differences in percentages of patients with a pCR.”

Statistical analysisFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

“The estimated treatment difference in the rate of pCR was 8.5 percentage points (95% confidence interval (CI), 4.2–12.8; P = 0.00005; Table ).”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete managed-access mechanism.

Evidence

paraphrase[Data availability section]

“The MSD data-sharing website (available at engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request.”

“Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access mechanism.

Evidence

paraphrase[Data availability section]

“The MSD data-sharing website (available at engagezone.msd.com/ds_documentation.php) outlines the process and requirements for submitting a data request.”

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“ClinicalTrials.gov identifier: NCT03725059”

AbstractFind in source

“However, these results should be interpreted with caution as these subgroups are underpowered, and the only objective of subgroup analyses is to explore convergent validity.”

Discussion ¶2Find in source

“To establish confidence, replication in other trials is absolutely essential.”

Discussion ¶2Find in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, funding, and COI statements, and limitations are discussed.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov identifier: NCT03725059 (https://clinicaltrials.gov/study/NCT03725059).”

“However, these results should be interpreted with caution as these subgroups are underpowered, and the only objective of subgroup analyses is to explore convergent validity.”

Discussion ¶2Find in source

“Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 27 references by DOI: 23 verified — 4 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly state compliance with the CONSORT reporting guideline.
Both reviewers flagged the absence of an explicit CONSORT mention, which is a standard expectation for RCT reporting.
2.
MEDIUMethics
In the Methods, explicitly state that the trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines.
One reviewer noted that regulatory compliance is only implied, and an explicit statement strengthens the ethics reporting.
3.
MEDIUMreporting
In the Methods, provide more detail on the randomization sequence generation (e.g., block size) to enhance reproducibility.
The randomization method is described, but additional details on sequence generation would improve transparency.
4.
MEDIUMstatistics
In the Statistical analysis section, clarify the handling of missing data for EFS and other secondary endpoints.
The paper does not explicitly describe missing data imputation or handling, which is important for survival analyses.
5.
MEDIUMdata code
In the Data Availability section, clarify the timeframe for data availability after product approval.
One reviewer suggested specifying when data will be available, which is a common requirement for data-sharing statements.
6.
MEDIUMreporting
In the Methods, specify the exact version of the AJCC staging criteria used for pCR assessment.
Providing the staging version ensures consistency and reproducibility of the pCR definition.
7.
MEDIUMstatistics
In the Results, report the number of patients with missing pCR data to fully address missing-data handling.
Transparency about missing data is essential for interpreting the primary endpoint.
8.
MEDIUMreporting
In the Discussion, explicitly acknowledge the lack of independent replication of the pCR finding within this trial.
While the paper notes the need for replication, explicitly stating that this is a single trial without independent replication would be clearer.
9.
MEDIUMreporting
In the Methods, describe the process for central confirmation of ER+/HER2- status to ensure consistency across sites.
Central confirmation of biomarker status is critical for trial validity and should be described.
10.
MEDIUMstatistics
In the Results, consider presenting p-values for secondary endpoints to fully report all outcomes.
Reporting p-values for secondary endpoints would enhance completeness, though it is not mandatory.
11.
LOWcopyedit
Fix the author list formatting: 'O’Shaughnessy Joyce Liu Zhenzhen' should have proper punctuation and spacing.
Correct author formatting is essential for indexing and professional presentation.
12.
LOWcopyedit
In the Abstract, consider reporting the p-value as '<0.001' for readability, or keep exact value consistently.
Consistency in p-value reporting improves readability.
13.
LOWcopyedit
In the Methods, clarify that the stratification by PD-L1 status applies only to Eastern Europe.
The sentence could be rephrased for better flow and clarity.
14.
LOWcopyedit
Ensure consistent spacing around plus/minus signs in 'ER + /HER2 − breast cancer' throughout the manuscript.
Minor formatting consistency improves professional appearance.
15.
LOWcopyedit
In the Results, Safety section, remove the space after the hyphen: 'non-Q wave' should be 'non-Q wave'.
Typographical spacing issue that should be corrected.
16.
LOWcopyedit
In the Methods, Statistical analysis, resolve the reference placeholder: 'The graphical method discussed in ref. was applied' should cite the specific reference.
Unresolved reference placeholders are a copyedit issue that must be fixed before publication.

Full text (52,247 chars)Analyzed: Aug 15, 2026